A Prospective Study of Diagnosis and Therapeutics in Intraocular Malignant Lymphoma
Not Applicable
- Conditions
- veitis suspected as Intraocular Malignant Lymphoma
- Registration Number
- JPRN-UMIN000007821
- Lead Sponsor
- Deportment of Ophthalmology, University of Tokyo Hospital
- Brief Summary
17 patients initiated and 16 completed the treatment. CNS relapse occurred in 2 and intraocular relapse in 3. 4-year PFS was 74.9% and 4-year OS was 86.3%. Of 11 patients without CNS involvement, 1 had CNS relapse and 3 intraocular relapse, and 4-year PFS was 72.7% and 4-year OS was 88.9%. No patients developed dementia/leukoencephalopathy. The combination of intravitreal chemotherapy, systemic chemotherapy and rdWBRT for B-cell PIOL showed a potential to reduce CNS relapse and improved 4-year PFS and OS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Not provided
Exclusion Criteria
Except for performance status 4
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic efficacy (sensitivity) of the diagnostic criteria Local recurrence ratio, systemic recurrence ratio, overall survival, progression-free survival
- Secondary Outcome Measures
Name Time Method Classification of the papanicolaou staing of the vitrecous specimens, concentration of IL10/IL-6 of vitreous samples, IgH monoclonarity, final visual acuity, site of systemic dissemination, term during therapy and recurrence